FOXM1 and hepatocellular carcinoma: For instance, individuals with high expression of FoxM1 were associated with a mean survival of 25.2 months in comparison to patients displaying low expression of FoxM1, who demonstrated a mean survival of 61.7 months (Supplementary Figure 1A), further strengthening the potential role of FoxM1 and its targets in determining survival in HCC patients.